166 related articles for article (PubMed ID: 30902528)
1. Dysphagia predicts poor outcome in late-stage Parkinson's disease.
Fabbri M; Coelho M; Abreu D; Guedes LC; Rosa MM; Godinho C; Cardoso R; Guimaraes I; Antonini A; Zibetti M; Lopiano L; Ferreira JJ
Parkinsonism Relat Disord; 2019 Jul; 64():73-81. PubMed ID: 30902528
[TBL] [Abstract][Full Text] [Related]
2. Response of non-motor symptoms to levodopa in late-stage Parkinson's disease: Results of a levodopa challenge test.
Fabbri M; Coelho M; Guedes LC; Chendo I; Sousa C; Rosa MM; Abreu D; Costa N; Godinho C; Antonini A; Ferreira JJ
Parkinsonism Relat Disord; 2017 Jun; 39():37-43. PubMed ID: 28389156
[TBL] [Abstract][Full Text] [Related]
3. Do patients with late-stage Parkinson's disease still respond to levodopa?
Fabbri M; Coelho M; Abreu D; Guedes LC; Rosa MM; Costa N; Antonini A; Ferreira JJ
Parkinsonism Relat Disord; 2016 May; 26():10-6. PubMed ID: 26972527
[TBL] [Abstract][Full Text] [Related]
4. Levodopa Effect and Motor Function in Late Stage Parkinson's Disease.
Rosqvist K; Horne M; Hagell P; Iwarsson S; Nilsson MH; Odin P
J Parkinsons Dis; 2018; 8(1):59-70. PubMed ID: 29480220
[TBL] [Abstract][Full Text] [Related]
5. Speech and Voice Response to a Levodopa Challenge in Late-Stage Parkinson's Disease.
Fabbri M; Guimarães I; Cardoso R; Coelho M; Guedes LC; Rosa MM; Godinho C; Abreu D; Gonçalves N; Antonini A; Ferreira JJ
Front Neurol; 2017; 8():432. PubMed ID: 28878734
[TBL] [Abstract][Full Text] [Related]
6. Substantia Nigra Neuromelanin as an Imaging Biomarker of Disease Progression in Parkinson's Disease.
Fabbri M; Reimão S; Carvalho M; Nunes RG; Abreu D; Guedes LC; Bouça R; Lobo PP; Godinho C; Coelho M; Gonçalves NC; Rosa MM; Antonini A; Ferreira JJ
J Parkinsons Dis; 2017; 7(3):491-501. PubMed ID: 28671143
[TBL] [Abstract][Full Text] [Related]
7. Parkinson's disease progression at 30 years: a study of subthalamic deep brain-stimulated patients.
Merola A; Zibetti M; Angrisano S; Rizzi L; Ricchi V; Artusi CA; Lanotte M; Rizzone MG; Lopiano L
Brain; 2011 Jul; 134(Pt 7):2074-84. PubMed ID: 21666262
[TBL] [Abstract][Full Text] [Related]
8. Dopaminergic Effect on Non-Motor Symptoms in Late Stage Parkinson's Disease.
Rosqvist K; Odin P; Hagell P; Iwarsson S; Nilsson MH; Storch A
J Parkinsons Dis; 2018; 8(3):409-420. PubMed ID: 30056433
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Rotigotine at Different Stages of Parkinson's Disease Symptom Severity and Disability: A Post Hoc Analysis According to Baseline Hoehn and Yahr Stage.
Giladi N; Nicholas AP; Asgharnejad M; Dohin E; Woltering F; Bauer L; Poewe W
J Parkinsons Dis; 2016 Oct; 6(4):741-749. PubMed ID: 27567886
[TBL] [Abstract][Full Text] [Related]
10. Disability in Activities of Daily Living and Severity of Dyskinesias Determine the Handicap of Parkinson's Disease Patients in Advanced Stage Selected to DBS.
Coelho M; Abreu D; Correia-Guedes L; Lobo PP; Fabbri M; Godinho C; Domingos J; Albuquerque L; Freitas V; Pereira JM; Cattoni B; Carvalho H; Reimão S; Rosa MM; Ferreira AG; Ferreira JJ
J Parkinsons Dis; 2017; 7(2):255-261. PubMed ID: 28157106
[TBL] [Abstract][Full Text] [Related]
11. Bilateral contemporaneous posteroventral pallidotomy for the treatment of Parkinson's disease: neuropsychological and neurological side effects. Report of four cases and review of the literature.
Ghika J; Ghika-Schmid F; Fankhauser H; Assal G; Vingerhoets F; Albanese A; Bogousslavsky J; Favre J
J Neurosurg; 1999 Aug; 91(2):313-21. PubMed ID: 10433321
[TBL] [Abstract][Full Text] [Related]
12. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
Goetz CG; Stebbins GT; Blasucci LM
Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
[TBL] [Abstract][Full Text] [Related]
13. High frequency of Depressive Disorders and Suicidal Phenomena in Late-Stage Parkinson´s Disease - A Cross-Sectional Study.
Chendo I; Fabbri M; Godinho C; Simões RM; Sousa CS; Coelho M; Voon V; Ferreira JJ
J Geriatr Psychiatry Neurol; 2023 Jul; 36(4):336-346. PubMed ID: 36278309
[TBL] [Abstract][Full Text] [Related]
14. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort.
Regnault A; Boroojerdi B; Meunier J; Bani M; Morel T; Cano S
J Neurol; 2019 Aug; 266(8):1927-1936. PubMed ID: 31073716
[TBL] [Abstract][Full Text] [Related]
15. The association between Parkinson's disease symptom side-of-onset and performance on the MDS-UPDRS scale part IV: Motor complications.
Bay AA; Hart AR; Michael Caudle W; Corcos DM; Hackney ME
J Neurol Sci; 2019 Jan; 396():262-265. PubMed ID: 30537631
[TBL] [Abstract][Full Text] [Related]
16. Motor and non-motor function predictors of mortality in Parkinson's disease.
Bugalho P; Ladeira F; Barbosa R; Marto JP; Borbinha C; Salavisa M; da Conceição L; Saraiva M; Fernandes M; Meira B
J Neural Transm (Vienna); 2019 Nov; 126(11):1409-1415. PubMed ID: 31385098
[TBL] [Abstract][Full Text] [Related]
17. Levodopa responsiveness of dysphagia in advanced Parkinson's disease and reliability testing of the FEES-Levodopa-test.
Warnecke T; Suttrup I; Schröder JB; Osada N; Oelenberg S; Hamacher C; Suntrup S; Dziewas R
Parkinsonism Relat Disord; 2016 Jul; 28():100-6. PubMed ID: 27158122
[TBL] [Abstract][Full Text] [Related]
18. Impact of non-motor symptoms on health-related and perceived quality of life in Parkinson's disease.
Santos-García D; de la Fuente-Fernández R
J Neurol Sci; 2013 Sep; 332(1-2):136-40. PubMed ID: 23890935
[TBL] [Abstract][Full Text] [Related]
19. Challenges in managing late-stage Parkinson's disease: Practical approaches and pitfalls.
Williams L; Qiu J; Waller S; Tsui D; Griffith J; Fung VSC
Aust J Gen Pract; 2022 Oct; 51(10):778-785. PubMed ID: 36184862
[TBL] [Abstract][Full Text] [Related]
20. Progression of motor impairment and disability in Parkinson disease: a population-based study.
Alves G; Wentzel-Larsen T; Aarsland D; Larsen JP
Neurology; 2005 Nov; 65(9):1436-41. PubMed ID: 16275832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
